Editorials

• Intrathecal gene therapy for neurologic disease in humans

• Special Editorial Feature: Learning from Our Failures

• Analyzing clinical observations to better understand and manage immune responses to AAV gene therapies

• ESGCT 2022: The New Normal for the Gene Therapy Community

• It Is Time to Call Anti-Asian Bias What It Is: Racism

• Women Lead Gene Therapy Science in 2021

• CRISPR Keeps Things Fresh: Next-Generation Tools for Gene Editing

• Gene and Cell Therapy for Inherited and Acquired Immune Deficiency

• Science Policy and Funding Implications of the 2020 U.S. Election

• Black Lives Matter to Gene Therapy

• Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy

• Barrie J. Carter: The Science and the Scientist

• Revisiting the "New" Inflammatory Toxicities of Adeno-Associated Virus Vectors

• A Message to Our Community in the Midst of the COVID-19 Pandemic

• Impact on Women's Health: Gene Therapy in Gynecologic Oncology

• Free Gene and Cell Therapy Services Offered by the National Heart, Lung, and Blood Institute of the National Institutes of Health

• 2020: Gene Therapy Enters Its Fourth Decade

• Ringing in the Changes

• Prime Editing: A Novel Cas9-Reverse Transcriptase Fusion May Revolutionize Genome Editing

• Epigenome Editing Strategies for Low Back Pain

• Getting Tough on Capsid Screening: Tough Decoys Enable Barcoding of Vectors Capable of both Entry and Expression

• Senior Gene Therapy Scientists Take a Stand Against Human Embryo Gene Editing

• New Horizons for Immune Gene Therapy

• Top Five Gene Therapy Stories of 2019

• DNA Vaccination in 2018: An Update

• Alpha-1 Antitrypsin Deficiency as a Candidate for Gene Editing

• Airway Basal Cells Are the Key for Cystic Fibrosis Gene Therapy

• Recombinant Adeno-Associated Virus-Based Gene Therapy for Disorders Detected by Newborn Screening: Inherent Limitations of This Approach

• Gene and Cell Therapy in China: Highlighting Excellence in the 21st Century ： 21

• Severe Toxicity in Nonhuman Primates and Piglets with Systemic High-Dose Administration of Adeno-Associated Virus Serotype 9-Like Vectors: Putting Patients First

• Gene and Cell Therapy in 2018: A Look Ahead

• Therapeutic Advances in Germany and Beyond

• The Renaissance of Gene and Cell Therapy: Florence 2016

• AAV Is Now a Medicine: We Had Better Get This Right

• The Negative Effects of Immigration Restrictions on the Gene Therapy Community

• Empty Adeno-Associated Virus Capsids: Contaminant or Natural Decoy?

• The Science Policy Implications of a Trump Presidency

• Gene Drives: Biological Shield or Ecological Menace?

• The Target's the Thing

• Why Human Gene Therapy Scientists Should Care About Model Organisms

• A Gene Therapy Scientist's Life Well-Lived

• Special Note from the Editor-in-Chief

• The Role of Patient Advocacy Organizations in Advancing Human Gene Therapy

• Transcription Activator-Like Nucleases Enable Allogeneic Chimeric Antigen Receptor-T Cell Therapy in Humans

• Ethical Implications of the Cost of Molecularly Targeted Therapies

• The End of the Beginning of Gene Therapy

• Therapeutic Germ Line Alteration: Has CRISPR/Cas9 Technology Forced the Question?

• Autoimmunity in a genetic disease—a cautionary tale

• Recent developments in the protection of pediatric research subjects